Clinical Relevance of EGFR in Breast Cancer: Precision Targeting for Better Outcomes

Authors

  • Dr Pravin Badhe Swalife Biotech Ltd North Point House, North Point Business Park, New Mallow Road, Cork (Republic of Ireland) Author
  • Dr K. P. Beena Department of Pharmaceutical Chemistry, Sri Ramakrishna Institute of Paramedical Sciences, College of Pharmacy, Coimbatore, Tamil Nadu Author
  • Dr T. Akelesh Department of Pharmaceutics, PPG College of Pharmacy, Coimbatore, Tamil Nadu Author

Keywords:

EGFR, Triple-Negative Breast Cancer, Biomarker Stratification, Precision Oncology, Clinical Trials, Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Decentralized Clinical Trials, AI-Assisted Patient Selection

Abstract

Background: Breast cancer remains a leading cause of cancer-related mortality worldwide, with triple-negative breast cancer (TNBC) representing a particularly aggressive subtype comprising 15–20% of all cases and characterized by poor prognosis, high recurrence rates, and limited targeted therapy options. Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is frequently overexpressed in TNBC (prevalence 13–89% across cohorts) and drives oncogenesis through dysregulated signaling pathways such as PI3K/AKT and MAPK, promoting proliferation, survival, and metastasis. EGFR expression and mutations serve as promising biomarkers for prognostic stratification and therapeutic selection, yet their clinical translation has been hampered by heterogeneous responses and resistance mechanisms.

 

Downloads

Published

2025-10-31

Issue

Vol. 1 No. 07 (2025)

Section

Articles